Novotech Expands Hong Kong Operations

Novotech, an Australian clinical-stage CRO, has open an enlarged, permanent office in Hong Kong. The new office will focus on Phase I trials in Hong Kong, which will take advantage of recently opened Phase I facilities at local universities. Hong Kong is, Novotech noted, a place officially recognized by China as a trial site for specific therapeutic areas. Three months ago, Novotech opened its first office in Shanghai, replacing its policy of working in China through partners. More details.... Share this with colleagues: // //